ArticleScientific reports2025
EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide, and its occurrence and development are intricately associated with the abnormal regulation of various genes and signaling pathways. Exosome Component 3(EXOSC3) is involved in the occurrence and growth of tumors. However, the exact mechanisms by which EXOSC3 influences HCC remain to be elucidated. Bioinformatics analysis method was used to detect the expression of EXOSC3 in HCC, qRT-PCR and Western blot were used to verify EXOSC3 expression in HCC cell lines.CCK-8 and colony formation assay was used to evaluate the effect of EXOSC3 on tumor proliferation, and validate the impact on cell migration and invasion through Transwell and Wound healing assay. Flow cytometry and Hochest staining were used to investigate the effect of EXOSC3 knockdown on the cell cycle and apoptosis of HCC. Western blot method was used to detect proteins expression. In HCC tissues, EXOSC3 mRNA and protein expression levels were notably higher than those in normal liver tissues and these levels correlated with poor prognosis. After knocking down EXOSC3, cell proliferation, colony formation, and metastasis were significantly inhibited in HCC. Flow cytometry and Western blot analyses showed that knockdown EXOSC3 promoted HCC cell apoptosis and inhibited cell cycle progression with reduced G1/S checkpoint protein expression. Furthermore, knockdown EXOSC3 activated P53 and decreased retinoblastoma protein (RB1) phosphorylation, suggesting that EXOSC3 functions via the P53 pathway in HCC. EXOSC3 has potential as a prognostic biomarker in HCC. Knockdown EXOSC3 leads to cell cycle arrest and consequently inhibits the proliferation of liver cancer cells by activating the P53 signaling pathway and concomitantly suppressing the expression of crucial regulatory proteins. These results not only establish EXOSC3 as a clinically relevant prognostic indicator but also highlight its therapeutic potential as a molecular target for HCC intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.